Lipoprotein(a) levels and their association with the severity of coronary artery lesions in patients with acute myocardial infarction undergoing percutaneous coronary intervention
Main Article Content
Abstract
This study was conducted to describe lipoprotein(a), identify related factors and evaluate the role of Lp(a) in discriminating the severity of coronary artery lesions according to the Gensini score. A cross-sectional descriptive study was performed on 80 patients at Ninh Thuan General Hospital from July 2025 to February 2026. The results demonstrated a median Lp(a) concentration of 121.7 mg/dL. Patients with limited physical activity (154.4 vs. 80.8 mg/dL), diabetes mellitus (184.8 vs. 91.7 mg/dL), and a history of previous myocardial infarction (199.1 vs. 105.0 mg/dL) had significantly higher Lp(a) levels (p < 0.05). Receiver operating characteristic (ROC) analysis showed that Lp(a) had good performance in identifying severe coronary artery disease, with an area under the curve (AUC) of 0.87 (95% CI: 0.79 – 0.96), indicating high discriminative ability. The optimal cut-off value was 187.3 mg/dL, yielding a sensitivity of 72.0% and a specificity of 94.5%. These findings suggest that higher Lp(a) levels are associated with more severe coronary artery lesions and may serve as a valuable biomarker for identifying severe coronary artery disease.
Article Details
Keywords
Acute myocardial infarction, Lipoprotein(a) levels, severe coronary artery lesions
References
2.. Kim RB, Kim JR. Epidemiology of myocardial infarction in Korea: hospitalization incidence, prevalence, and mortality. Epidemiol Health. 2022;44(1). doi: 10.4178/epih.e2022057.
3. Singh A, Puhan R. Small Dense Low-Density Lipoprotein for Risk Prediction of Acute Coronary Syndrome. Cardiol Res. 2021;12(4):251-257. doi: 10.14740/cr1254.
4. Bourlond B, Dupré M, Qanadli SD, Eeckhout E. Two complex coronary artery abnormalities discovered after an acute coronary syndrome: A case report. Ann Cardiol Angeiol. 2024;73(6):101838. doi:10.1016/j.ancard.2024.101838.
5. Khan Z. Aberrant Left Coronary Artery Origin in a Patient Presenting With Acute Coronary Syndrome. Cureus. 2024;16(3):e55810. doi:10.7759/cureus.55810.
Saleh M, Ambrose JA. Understanding myocardial infarction. F1000Res. 2018;7(1):F1000 doi:10.12688/f1000research. 15096.1.
6. Ziogos E, Vavuranakis MA, Harb T, et al. Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up. Eur Heart J Open. 2023;3(2):oead035. doi:10.1093/ehjopen/oead035.
7. Wang Z, Xiao S, Liu N. Association of lipoprotein(a) with coronary severity in patients with new-onset acute myocardial infarction: A large cross-sectional study. Clin Chim Acta. 2023;540:117220. doi:10.1016/j.cca.2023.117220.
8. Sun D, Zhao X, et al. Lipoprotein (a) as a Marker for Predicting the Presence and Severity of Coronary Artery Disease in Untreated Chinese Patients Undergoing Coronary Angiography. Biomed Environ Sci. 2018;31(4):253-260. doi:10.3967/bes2018.033.
9. Liu H, Wang L, Wang H, et al. The Association of Lipoprotein(a) with Major Adverse Cardiovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies. Rev Cardiovasc Med. 2025;26(5):27376. doi:10.31083/RCM27376.
10. Bộ Y tế. Hướng dẫn chẩn đoán và xử trí hội chứng mạch vành cấp. 2019;5-13.
11. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191.
13. Cesaro A, Acerbo V, Scialla F, et al. Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease. Nutr Metab Cardiovasc Dis. 2024;35(5):103843. doi:10.1016/j.numecd.2024.103843.
14. Lampsas S, Xenou M, Oikonomou E, et al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28(3):969. Published 2023 Jan 18. doi:10.3390/molecules28030969.